Bladder cancer encompasses a wide mutational spectrum of genetic changes, with mutations in FGFR3 (activating mutations in ~20%), TP53 (loss-of-function mutations in ~50%), and ERBB2 (amplifications in ~10%) being particularly common [32,33] (Table 1). The gene discussed is TP53; the disease is urinary bladder carcinoma.